Landmark and longitudinal exposure-response analyses in drug development

被引：16

作者：

Hu, Chuanpu ^{[1
]}

Zhou, Honghui ^{[1
]}

Sharma, Amarnath ^{[1
]}

机构：

[1] Janssen Res & Dev LLC, Global Clin Pharmacol, POB 776,1400 McKean Rd, Spring House, PA 19477 USA

来源：

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2017年 / 44卷 / 05期

关键词：

4 BASIC MODELS;

D O I：

10.1007/s10928-017-9534-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：503 / 507

页数：5

共 8 条

[1] Pattern Recognition in Pharmacodynamic Data Analysis [J].

Gabrielsson, Johan ;

Hjorth, Stephan .

AAPS JOURNAL, 2016, 18 (01) :64-91

[2] Exposure-Response Modeling of Clinical End Points Using Latent Variable Indirect Response Models [J].

Hu, C. .

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (06)

[3] Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis [J].

Hu, Chuanpu ;

Zhou, Honghui .

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 (01) :45-54

[4] Latent variable indirect response modeling of categorical endpoints representing change from baseline [J].

Hu, Chuanpu ;

Xu, Zhenhua ;

Mendelsohn, Alan M. ;

Zhou, Honghui .

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 (01) :81-91

[5] Integrated functions for four basic models of indirect pharmacodynamic response [J].

Krzyzanski, W ;

Jusko, WJ .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (01) :67-72

[6] Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development [J].

Overgaard, R. V. ;

Ingwersen, S. H. ;

Tornoe, C. W. .

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2015, 4 (10) :565-575

[7] Characterization of four basic models of indirect pharmacodynamic responses [J].

Sharma, A ;

Jusko, WJ .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1996, 24 (06) :611-635

[8]

Urquhart J., 2002, SIMULATION DESIGNING

← 1 →